Post-transplantation antibody monitoring and HLA antibody epitope identification

被引:45
作者
Cai, Junchao [1 ]
Terasaki, Paul I. [1 ]
机构
[1] Terasaki Fdn Lab, Los Angeles, CA 90064 USA
关键词
D O I
10.1016/j.coi.2008.07.008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We earlier reviewed the reasons to believe that HLA antibodies are the cause of chronic rejection. In this review we shall focus on two questions: first, why is it important to test transplant recipients for alloantibody post-transplantation? Recent largescale prospective studies on the effect of alloantibodies on graft survival showed that rates of graft failure more than doubled in recipients who had alloantibodies compared with antibody-free patients. The causal relationship between alloantibody and transplant rejection - especially chronic rejection - has been demonstrated both experimentally and clinically. We recommend universal testing of allograft recipients for antibodies since that will help clinicians identify this obvious risk factor and take appropriate action to minimize deterioration of transplant function. Second, why is it important to identify HLA antibody epitopes? Since HLA antibody is a potential cause of graft rejection, identifying the epitope - or antigenic determinant - to which an antibody binds, becomes very important. Such identification lets clinicians target the real transplant antigen and may lay a foundation for the development of new treatments and/or new matching strategies to reduce the occurrence of antibody-mediated rejection (AMR). Now that natural HLA antibodies have been identified; it is important to distinguish these from donorspecific epitopes. The establishment of 103 HLA class I epitopes, 83 class 11, and 7 major-histocompatibility-complex class I-related chain A (MICA) epitopes is reviewed. Single antigen bead technology has been important in identifying the epitopes by experiment.
引用
收藏
页码:602 / 606
页数:5
相关论文
共 37 条
[1]   Serum analysis after transplant nephrectomy reveals restricted antibody specificity patterns against structurally defined HLA class I mismatches [J].
Adeyi, OA ;
Girnita, AL ;
Howe, J ;
Marrari, M ;
Awadalla, Y ;
Askar, M ;
Martell, J ;
Zeevi, A ;
Shapiro, R ;
Nalesnik, M ;
Randhawa, P ;
Demetris, AJ ;
Duquesnoy, RJ .
TRANSPLANT IMMUNOLOGY, 2005, 14 (01) :53-62
[2]   Development of nondonor-specific HLA-DR antibodies in allograft recipients is associated with shared epitopes with mismatched donor DR antigens [J].
Cai, J. ;
Terasaki, P. I. ;
Mao, Q. ;
Pham, T. ;
El-Awar, N. ;
Lee, J. -H. ;
Rebellato, L. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2006, 6 (12) :2947-2954
[3]   Humoral theory of transplantation: Mechanism, prevention, and treatment [J].
Cai, J ;
Terasaki, PI .
HUMAN IMMUNOLOGY, 2005, 66 (04) :334-342
[4]  
CAI J, 2007, CLIN TRANSPLANT, P103
[5]   Human leukocyte antigen antibodies for monitoring transplant patients [J].
Cai, JC ;
Terasaki, PI .
SURGERY TODAY, 2005, 35 (08) :605-612
[6]   Human leukocyte antigen class II DQ alpha and beta epitopes identified from sera of kidney allograft recipients [J].
Deng, Chun-Tsan ;
El-Awar, Nadim ;
Ozawa, Miyuki ;
Cai, Junchao ;
Lachmann, Nils ;
Terasaki, Paul I. .
TRANSPLANTATION, 2008, 86 (03) :452-459
[7]  
Dickenmann M, 2006, CLIN NEPHROL, V65, P173
[8]   HLAMatchmaker: A molecularly based algorithm for histocompatibility determination. V. Eplet matching for HLA-DR, HLA-DQ, and HLA-DP [J].
Duquesnoy, Rene J. ;
Askar, Medhat .
HUMAN IMMUNOLOGY, 2007, 68 (01) :12-25
[9]   A structurally based approach to determine HLA compatibility at the humoral immune level [J].
Duquesnoy, Rene J. .
HUMAN IMMUNOLOGY, 2006, 67 (11) :847-862
[10]   HLAMatchmaker: A molecularly based algorithm for histocompatibility determination. II. Verification of the algorithm and determination of the relative immunogenicity triplet-defined of amino acid epitopes [J].
Duquesnoy, RJ ;
Marrari, M .
HUMAN IMMUNOLOGY, 2002, 63 (05) :353-363